2022
DOI: 10.1007/s11764-022-01194-z
|View full text |Cite
|
Sign up to set email alerts
|

Treating persistent pain after breast cancer: practice gaps and future directions

Abstract: This paper discusses the growing problem of persisting pain after successful treatment of breast cancer and presents recommendations for improving pain-related outcomes for this group. We discuss the dominant treatment approach for persisting pain post-breast cancer treatment and draw contrasts with contemporary treatment approaches to persistent pain in noncancer-related populations. We discuss modern application of the biopsychosocial model of pain and the notion of variable sensitivity within the pain syste… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 97 publications
(118 reference statements)
0
5
0
Order By: Relevance
“…In addition, our data suggest that neuropathic pain is underdiagnosed and undertreated in cancer survivors, given that most patients were on Step 1 analgesics [40], and only a few received drugs targeting neuropathic pain. Unlike awareness of chemotherapyinduced neuropathy, which seems widespread, post-surgical neuropathic pain might be a relevant and frequently overlooked health problem in cancer survivors (especially in breast cancer survivors) [41]. Furthermore, many such patients might have a neuropathic component even in the absence of an apparent neural injury [41,42].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, our data suggest that neuropathic pain is underdiagnosed and undertreated in cancer survivors, given that most patients were on Step 1 analgesics [40], and only a few received drugs targeting neuropathic pain. Unlike awareness of chemotherapyinduced neuropathy, which seems widespread, post-surgical neuropathic pain might be a relevant and frequently overlooked health problem in cancer survivors (especially in breast cancer survivors) [41]. Furthermore, many such patients might have a neuropathic component even in the absence of an apparent neural injury [41,42].…”
Section: Discussionmentioning
confidence: 99%
“…Unlike awareness of chemotherapyinduced neuropathy, which seems widespread, post-surgical neuropathic pain might be a relevant and frequently overlooked health problem in cancer survivors (especially in breast cancer survivors) [41]. Furthermore, many such patients might have a neuropathic component even in the absence of an apparent neural injury [41,42]. Adopting appropriate and simple neuropathic pain diagnostic tools (e.g., DN4) in the routine clinical practice of medical oncologists and defining appropriate treatment and referral strategies, for patients with neuropathic features, to pain specialists seems to be a good and underused therapeutic option which could improve health outcomes [43].…”
Section: Discussionmentioning
confidence: 99%
“…Earlier research investigated the presence of "central sensitization pain" using of the Central Sensitization Inventory, a questionnaire to assess self-reported signs of central sensitization (De Groef et al, 2018;Leysen et al, 2019;Manfuku et al, 2019). The use of solely questionnaires for the evaluation of somatosensory functioning to unravel "central sensitization pain" lacks correlation with existing QST protocols in BCS and chronic musculoskeletal pain (Cliton Bezerra et al, 2021;Dams et al, 2022). Even though not all studies identified the location and/or type of pain, they did find presence of "central sensitization pain" in BCS experiencing persistent pain (Leysen et al, 2019;Manfuku et al, 2019).…”
Section: Postmastectomy Pain Syndromementioning
confidence: 99%
“…BCS can experience a multitude of side effects related to altered somatosensory functioning after breast cancer treatment. One side effect does not exclude the other and it is possible, and also probable that some BCS experience multiple side effects at the same time (De Groef et al, 2022; Leysen et al, 2019). It is apparent that all the aforementioned conditions (PMPS, AIMS, and CIPN) affect the quality of life and return to work (De Groef et al, 2022).…”
Section: Commentarymentioning
confidence: 99%
“…[19][20][21][22][23] The biomedical vision on pain may indirectly hamper functioning, viewing pain as a sign of tissue damage. [24] This view might be true in the acute phase, as pain then serves a protective role, but the contributing role of psychosocial factors increases with pain persistence. PNE explains the neurobiology and neurophysiological concepts of pain within the nervous system, so patients understand how their pain is produced.…”
Section: Introductionmentioning
confidence: 99%